Invitation to comment on a trial
of a genetically modified vaccine against devil facial tumour disease in Tasmanian devils.

The Gene Technology Regulator is assessing an application from the University of Tasmania to conduct a trial, under limited and controlled conditions, of a genetically modified (GM) vaccine for the prevention and/or treatment of devil facial tumour disease in Tasmanian devils. The GM vaccine would be administered to Tasmanian devils kept in enclosures within trial sites in Tasmania.

The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and welcomes written submissions relating to the protection of human health and safety and the environment prior to making a decision on whether to issue the licence. The consultation RARMP and related information can be obtained via our website (search for DIR 195), or from the contacts below. Submissions should reference DIR 195 and be received by 12 May 2023.

Office of the Gene Technology Regulator
MDP 54 GPO Box 9848 CANBERRA ACT 2601

Telephone: 1800 181 030   Website: www.ogtr.gov.au

E-mail: ogtr@health.gov.au